Contrasting Newcardio (NWCI) & Zynex (ZYXI)

Newcardio (OTCMKTS:NWCI) and Zynex (OTCMKTS:ZYXI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.


This table compares Newcardio and Zynex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Newcardio N/A N/A N/A
Zynex 33.33% 152.81% 95.46%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Newcardio and Zynex, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Newcardio 0 0 0 0 N/A
Zynex 0 0 1 0 3.00

Zynex has a consensus target price of $7.00, indicating a potential upside of 133.33%. Given Zynex’s higher possible upside, analysts clearly believe Zynex is more favorable than Newcardio.

Valuation and Earnings

This table compares Newcardio and Zynex’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Newcardio N/A N/A N/A N/A N/A
Zynex $23.43 million 4.26 $7.36 million $0.22 13.64

Zynex has higher revenue and earnings than Newcardio.

Volatility and Risk

Newcardio has a beta of 6.54, suggesting that its stock price is 554% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Zynex shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Zynex beats Newcardio on 7 of the 8 factors compared between the two stocks.

Newcardio Company Profile

NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.

Zynex Company Profile

Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Receive News & Ratings for Newcardio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newcardio and related companies with's FREE daily email newsletter.

Leave a Reply